Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8,057.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,849 shares of the company's stock after purchasing an additional 10,716 shares during the quarter. GAMMA Investing LLC's holdings in Akero Therapeutics were worth $439,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Rhumbline Advisers raised its position in shares of Akero Therapeutics by 1.3% during the 4th quarter. Rhumbline Advisers now owns 105,686 shares of the company's stock valued at $2,940,000 after buying an additional 1,310 shares in the last quarter. Handelsbanken Fonder AB raised its position in Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company's stock worth $584,000 after purchasing an additional 1,000 shares during the period. Proficio Capital Partners LLC purchased a new stake in Akero Therapeutics in the 4th quarter worth about $320,000. Charles Schwab Investment Management Inc. raised its position in Akero Therapeutics by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock worth $15,042,000 after purchasing an additional 8,096 shares during the period. Finally, AlphaQuest LLC raised its position in Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after purchasing an additional 8,147 shares during the period.

Insiders Place Their Bets

In related news, Director G. Walmsley Graham acquired 91,309 shares of the stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average cost of $44.75 per share, for a total transaction of $4,086,077.75. Following the completion of the purchase, the director now owns 1,091,309 shares of the company's stock, valued at approximately $48,836,077.75. This represents a 9.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Patrick Lamy sold 875 shares of Akero Therapeutics stock in a transaction on Friday, June 20th. The stock was sold at an average price of $54.59, for a total transaction of $47,766.25. Following the sale, the vice president now owns 31,698 shares of the company's stock, valued at $1,730,393.82. The trade was a 2.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 232,979 shares of company stock valued at $10,935,650. 7.07% of the stock is currently owned by insiders.

Akero Therapeutics Stock Down 0.3%

NASDAQ AKRO traded down $0.17 on Monday, hitting $54.03. The stock had a trading volume of 1,271,985 shares, compared to its average volume of 1,014,119. The business's fifty day moving average price is $45.88 and its 200 day moving average price is $41.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.80 and a quick ratio of 16.80. Akero Therapeutics, Inc. has a 52-week low of $21.02 and a 52-week high of $58.40. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -27.71 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Wall Street Analyst Weigh In

AKRO has been the topic of a number of research reports. Citigroup reduced their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. HC Wainwright raised their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Finally, Bank of America lifted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a report on Tuesday, May 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.